The sustained delivery of resveratrol or a defined grape powder inhibits new blood vessel formation in a mouse model of choroidal neovascularization

Molecules

Volumn 19, Issue 11, 2014, Pages 17578-17603

  Kanavi, Mozhgan Rezaie ^a   Darjatmoko, Soesiawati ^b   Wang, Shoujian ^b   Azari, Amir A ^c   Farnoodian, Mitra ^b   Kenealey, Jason D ^d   Van Ginkel, Paul R ^b   Albert, Daniel M ^b   Sheibani, Nader ^b   Polans, Arthur S ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c WILLS EYE HOSPITAL   (United States)

^d BRIGHAM YOUNG UNIVERSITY   (United States)

Author keywords

Age related macular degeneration; Angiogenesis; Choroidal neovascularization; Grape constituents; Natural products; Resveratrol

Indexed keywords

ANGIOGENESIS INHIBITOR; CELL ADHESION MOLECULE; DELAYED RELEASE FORMULATION; POWDER; PROTEIN KINASE B; PROTEIN P53; RESVERATROL; STILBENE DERIVATIVE;

ADMINISTRATION AND DOSAGE; ANIMAL; BRUCH MEMBRANE; C57BL MOUSE; CHEMISTRY; CHOROIDAL NEOVASCULARIZATION; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE MICROSCOPY; LASER; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; POWDER; PROCEDURES; VITIS;

ANGIOGENESIS INHIBITORS; ANIMALS; BRUCH MEMBRANE; CELL ADHESION MOLECULES; CHOROIDAL NEOVASCULARIZATION; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FEMALE; LASERS; MICE; MICE, INBRED C57BL; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; POWDERS; PROTO-ONCOGENE PROTEINS C-AKT; STILBENES; TUMOR SUPPRESSOR PROTEIN P53; VITIS;

EID: 84912557427     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules191117578     Document Type: Article

References (87)

1. Eye Diseases Prevalence Research Group. Prevalence of age related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122, 564-572.
2. Ambati, J.; Ambati, B.K.; Yoo, S.H.; Lanchulev, S.; Adamis, A.P. Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 2003, 48, 257-293.
3. Jager, R.D.; Mieler, W.F.; Miller, J.W. Age-related macular degeneration. N. Engl. J. Med. 2008, 358, 2606-2617.
4. Cheung, L.K.; Eaton, A. Age-Related Macular Degeneration. Pharmacotherapy 2013, 33, 838-855.
5. Brown, D.M.; Michels, M.; Kaiser, P.K.; Heier, J.S.; Sy, J.P.; Lanchulev, T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009, 116, 57-65.
6. Sivaprasad, S.; Hykin, P. What is new in the management of wet age-related macular degeneration? Br. Med. Bull. 2013, 105, 201-211.
7. Bressler, N.M. Antiangiogenic approaches to age-related macular degeneration today. Ophthalmology 2009, 116, S15-S23.
8. Yamazaki, T.; Koizumi, H.; Yamagishi, T.; Kinoshita, S. Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results. Ophthalmology 2012, 119, 1621-1627.
9. Martin, D.F.; Maguire, M.G.; Fine, S.L.; Ying, G.S.; Jaffe, G.J.; Grunwald, J.E.; Toth, C.; Redford, M.; Ferris, F.L. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012, 119, 1388-1398.
10. Fintak, D.R.; Shah, G.K.; Blinder, K.J.; Regillo, C.D.; Pollack, J.; Heier, J.S.; Hollands, H.; Sharma, S. Incidence of endophthalmitis related to intravitreal injection of bevacizumab and ranibizumab. Retina 2008, 28, 1395-1399.
11. Hoevenaars, N.E.; Gans, D.; Missotten, T.; van Rooij, J.; Lesaffre, E.; van Meurs, J.C. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: Case series and literature review. Ophthalmologica 2012, 228, 143-147.
12. HaHarikumar, K.B.; Aggrawal, B.B. Resveratrol: A multitargeted agent for age-associated chronic diseases. Cell Cycle 2008, 7, 1020-1035.
13. Shakibaei, M.; Harikumar, K.B.; Aggrawal, B.B. Resveratrol addiction: To die or not to die. Mol. Nutr. Food Res. 2009, 53, 115-128.
14. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"? Eur. J. Endocrinol. 1998, 138, 619-620.
15. Renaud, S.; de Lorgeril, M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339, 1523-1526.
16. Ray, P.S.; Maulik, G.; Cordis, G.A.; Bertelli, A.A.; Bertelli, A.; Das, D.K. The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic. Biol. Med. 1999, 27, 160-169.
17. Lekli, I.; Szabo, G.; Juhasz, B.; Das, S.; Das, M.; Varga, E.; Szendrei, L.; Gesztelyi, R.; Varadi, J.; Bak, I.; et al. Protective mechanism of resveratrol against ischemia-reperfusion-induced damage in hearts obtained from Zucker obese rats: The role of GLUT-4 and endothelin. Am. J. Physiol. Heart Circ. Physiol. 2008, 294, H859-H866.
18. Dong, W.; Li, N.; Gao, D.; Zhen, H.; Zhang, X.; Li, F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J. Vasc. Surg. 2008, 48, 709-714.
19. Sakata, Y.; Zhuang, H.; Kwansa, H.; Koehler, R.C.; Dore, S. Resveratrol protects against experimental stroke: Putative neuroprotective role of heme oxygenase 1. Exp. Neurol. 2010, 224, 325-329.
20. Shin, J.A.; Lee, H.; Lim, Y.K.; Koh, Y.; Choi, J.H.; Park, E.M. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J. Neuroimmunol. 2010, 227, 93-100.
21. Sun, A.Y.; Wang, Q.; Simonyi, A.; Sun, G.Y. Resveratrol as a therapeutic agent for neurodegenerative diseases. Mol. Neurobiol. 2010, 41, 375-383.
22. Aggrawal, B.B.; Bhardwaj, A.; Aggrawal, R.S.; Seeram, N.P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies. Anticancer Res. 2004, 24, 2783-2840.
23. Jang, M.; Cai, L.; Udeani, G.O.; Slowing, K.V.; Thomas, C.F.; Beecher, C.W.; Fong, H.H.; Farnsworth, N.R.; Kinghorn, A.D.; Mehta, R.G.; et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275, 218-220.
24. Athar, M.; Back, J.H.; Tang, X.; Kim, K.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Phamacol. 2007, 224, 274-283.
25. Delmas, D.; Lancon, A.; Colin, D.; Jannin, B.; Latruffe, N. Resveratrol as a chemopreventive agent: A promising molecule for fighting cancer. Curr. Drug Targets 2006, 7, 423-442.
26. Sharma, S.; Anjaneyulu, M.; Kulkarni, S.K.; Chopra, K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006, 76, 69-75.
27. Su, H.C.; Hung, L.M.; Chen, J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290, E1339-E1346.
28. Szkudelski, T.; Szkudelska, K. Anti-diabetic effects of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 34-39.
29. De La Lastra, C.A.; Villegas, I. Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications. Mol. Nutr. Food Res. 2005, 49, 405-430.
30. Lee, B.; Moon, S.K. Resveratrol inhibits TNF-alpha-induced proliferation and matrix metalloproteinase expression in human vascular smooth muscles. J. Nutr. 2005, 135, 2767-2773.
31. Martin, A.R.; Villegas, I.; Sanchez-Hidalgo, M.; de la Lastra, C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 2006, 147, 873-885.
32. Rahman, I.; Marwick, J.; Kirkham, P. Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-kappaB and proinflammatory gene expression. Biochem. Pharmacol. 2004, 68, 1255-1267.
33. Valenzano, D.R.; Terzibasi, E.; Genade, T.; Cattaneo, A.; Domenici, L.; Cellerino, A. Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 2006, 16, 296-300.
34. Valenzano, D.R.; Cellerino, A. Resveratrol and the pharmacology of aging: A new vertebrate model to validate an old molecule. Cell Cycle 2006, 5, 1027-1032.
35. Kaga, S.; Zhan, L.; Matsumoto, M.; Maulik, N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell. Cardiol. 2005, 39, 813-822.
36. Khan, A.A.; Dace, D.S.; Ryazanov, A.G.; Kelly, J.; Apte, R.S. Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am. J. Pathol. 2010, 177, 481-492.
37. Chen, Y.; Tseng, S.H. Review. Pro- and anti-angiogenesis effects of resveratrol. In Vivo 2007, 21, 365-370.
38. Robich, M.P.; Osipov, R.M.; Nezafat, R.; Feng, J.; Clements, R.T.; Bianchi, C.; Boodhwani, M.; Coady, M.A.; Laham, R.J.; Sellke, F.W. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010, 122, S142-S149.
39. Srivastava, R.K.; Unterman, T.G.; Shankar, S. FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol. Cell. Biochem. 2010, 337, 201-212.
40. Kimura, Y.; Sumiyoshi, M.; Baba, K. Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. Cancer Sci. 2008, 99, 2083-2096.
41. Garvin, S.; Ollinger, K.; Dabrosin, C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006, 231, 113-122.
42. Chen, J.C.; Chen, Y.; Lin, J.H.; Wu, J.M.; Tseng, SH. Resveratrol suppresses angiogenesis in gliomas: Evaluation by color Doppler ultrasound. Anticancer Res. 2006, 26, 1237-1245.
43. Bagchi, D.; Garg, A.; Krohn, R.L.; Bagchi, M.; Tran, M.X.; Stohs, S.J. Oxygen free radical scavenging abilities of vitamins C and E, and a grape seed proanthocyanidin extract in vitro. Res. Commun. Mol. Pathol. Pharmacol. 1997, 95, 179-189.
44. Bagchi, D.; Bagchi, M.; Stohs, S.J.; Ray, S.D.; Sen, C.K.; Preuss, H.G. Cellular protection with proanthocyanidins derived from grape seeds. Ann. N. Y. Acad. Sci. 2002, 957, 260-270.
45. Terra, X.; Montagut, G.; Bustos, M.; Llopiz, N.; Ardèvol, A.; Bladé, C.; Fernández-Larrea, J.; Pujadas, G.; Salvadó, J.; Arola, L.; et al. Grape-seed procyanidins prevent low-grade inflammation by modulating cytokine expression in rats fed a high-fat diet. J. Nutr. Biochem. 2009, 20, 210-218.
46. Ye, X.; Krohn, R.L.; Liu, W.; Joshi, S.S.; Kuszynski, C.A.; McGinn, T.R.; Bagchi, M.; Preuss, H.G.; Stohs, S.J.; Bagchi, D. The cytotoxic effects of a novel IH636 grape seed proanthocyanidin extract on cultured human cancer cells. Mol. Cell. Biochem. 1999, 196, 99-108.
47. Pataki, T.; Bak, I.; Kovacs, P.; Baqchi, D.; Das, D.K.; Tosaki, A. Grape seed proanthocyanidins improved cardiac recovery during reperfusion after ischemia in isolated rat hearts. Am. J. Clin. Nutr. 2002, 75, 894-899.
48. Bagchi, D.; Garg, A.; Krohn, R.L.; Bagchi, M.; Bagchi, D.J.; Stohs, S. Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice. Gen. Pharm. 1998, 30, 771-776.
49. Song, X.; Xu, H.; Feng, Y.; Li, X.; Lin, M.; Cao, L. Protective effect of grape seed proanthocyanidins against liver ischemic reperfusion injury: Particularly in diet-induced obese mice. Int. J. Biol. Sci. 2012, 8, 1345-1362.
50. Khanna, S.; Roy, S.; Bagchi, D.; Bagchi, M.; Sen, C.K. Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic. Biol. Med. 2001, 31, 38-42.
51. Khanna, S.; Venojarvi, M.; Roy, S.; Sharma, N.; Trikha, P.; Bagchi, D.; Bagchi, M.; Sen, C.K. Dermal wound healing properties of redox-active grape seed proanthocyanidins. Free Radic. Biol. Med. 2002, 33, 1089-1096.
52. Pesca, M.S.; Dal Piaz, F.; Sanogo, R.; Vassallo, A.; Bruzual de Abreu, M.; Rapisarda, A.; Germanò, M.P.; Certo, G.; de falco, S.; de tommasi, N.; et al. Bioassay-guided isolation of proanthocyanidins with antiangiogenic activities. J. Nat. Prod. 2013, 76, 29-35.
53. Huang, S.; Yang, N.; Liu, Y.; Hu, L.; Zhao, J.; Gao, J.; Li, Y.; Li, C.; Zhang, X.; Huang, T. Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling. Nutr. Res. 2012, 32, 530-536.
54. Li, W.; Jiang, D. Effect of resveratrol on bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity. J. Pediatr. Ophthalmol. Strabismus 2012, 49, 230-235.
55. Hua, J.; Guerin, K.I.; Chen, J.; Michán, S.; Stahl, A.; Krah, N.M.; Seaward, M.R.; Dennison, R.J.; Juan, A.M.; Hatton, C.J.; et al. Resveratrol inhibits pathologic retinal neovascularization in Vldlr(-/-) mice. Investig. Ophthalmol. Vis. Sci. 2011, 52, 2809-2816.
56. Kim, Y.H.; Kim, Y.S.; Roh, G.S.; Choi, W.S.; Cho, G.J. Resveratrol blocks diabetes-induced early vascular lesions and vascular endothelial growth factor induction in mouse retinas. Acta Ophthalmol. 2012, 90, 31-37.
57. Sareen, D.; van Ginkel, P.R.; Takach, J.C.; Mohiuddin, A.; Darjatmoko, S.R.; Albert, D.M.; Polans, A.S. Mitochondria are the primary target during resveratrol-induced apoptosis in human retinoblastoma cells. Investig. Ophthalmol. Vis. Sci. 2006, 47, 3708-3716.
58. Sareen, D.; Darjatmoko, S.R.; Albert, D.M.; Polans, A.S. Mitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer. Mol. Pharm. 2007, 72, 1466-1475.
59. Van Ginkel, P.R.; Sareen, D.; Subramanian, L.; Walker, Q.; Darjatmoko, S.R.; Lindstrom, M.; Kulkarni, A.; Albert, D.M.; Polans, A.S. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin. Cancer Res. 2007, 13, 5162-5169.
60. Teodoro, J.G.; Evans, S.K.; Green, M.R. Inhibition of tumor angiogenesis by p53: A new role for the guardian of the genome. J. Mol. Med. 2007, 85, 1175-1186.
61. Busquets, S.; Ametller, E.; Fuster, G.; Olivan, M.; Raab, V.; Argilés, J.M.; Lopez-Soriano, F.J. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett. 2007, 245, 144-148.
62. Bhattacharya, S.S.; Darjatmoko, S.R.; Polans, A.S. The inactivation of Akt/PKB by resveratrol regulates the malignant properties of cutaneous melanoma. Melanoma Res. 2011, 21, 180-187.
63. Karar, J.; Maity, A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci. 2011, 4, 51-65.
64. Berridge, M.J.; Lipp, P.; Bootman, M.D. The versatility and universality of calcium signaling. Nat. Rev. Mol. Cell Biol. 2000, 1, 11-21.
65. Campos-Toimil, M.; Elies, J.; Alvarez, E.; Verde, I.; Orallo, F. Effects of trans- and cis-resveratrol on Ca2+ handling in A7r5 vascular myocytes. Eur. J. Pharmacol. 2007, 577, 91-99.
66. Ma, X.; Tian, X.; Huang, X.; Yan, F.; Qiao, D. Resveratrol-induced mitochondrial dysfunction and apoptosis are associated with calcium and mCICR-mediated MPT activation in HepG2 cells. Mol. Cell. Biochem. 2007, 302, 99-109.
67. Miki, K.; Miki, A.; Matsuoka, M.; Muramatsu, D.; Hackett, S.F.; Campochiaro, P.A. Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor. Ophthalmology 2009, 116, 1748-1754.
68. Walle, T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 9-15.
69. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32, 1377-1382.
70. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. 2005, 49, 472-481.
71. Gescher, A.J.; Steward, W.P. Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: A conundrum. Cancer Epidemiol. Biomark. Prev. 2003, 12, 953-957.
72. Asensi, M.; Medina, I.; Ortega, A.; Carretero, J.; Baño, M.C.; Obrador, E.; Estrela, J.M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 2002, 33, 387-398.
73. Robich, M.P.; Chu, L.M.; Chaudray, M.; Nezafat, R.; Han, Y.; Clements, R.T.; Laham, R.J.; Manning, W.J.; Coady, M.A.; Sellke, F.W. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 2010, 148, 453-462.
74. Tseng, S.-H.; Lin, S.-M.; Chen, J.-C.; Su, Y.H.; Huang, H.Y.; Chen, C.K.; Lin, P.Y.; Chen, Y. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin. Cancer Res. 2004, 10, 2190-2202.
75. Dudley, J.; Das, S.; Mukherjee, S.; Das, D.K. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J. Nutr. Biochem. 2009, 20, 443-452.
76. Nagineni, C.; Raju, R.; Nagineni, K.; Kommineni, V.; Cherukuri, A.; Kutty, R.; Hooks, J.; Detrick, B. Resveratrol suppresses expression of VEGF by human retinal pigment epithelial cells: Potential nutraceutical for age-related macular degeneration. Aging Dis. 2014, 5, 88-100.
77. Stewart, E.; Samaranayake, G.; Browning, A.; Hopkinson, A.; Amoaku, W. Comparison of choroidal and retinal endothelial cells: Characteristics and response to tVEGF isoforms and anti-VEGF treatments. Exp. Eye Res. 2011, 93, 761-766.
78. Nagai, N.; Kubota, S.; Tsubota, K.; Ozawa, Y. Resveratrol prevents the development of choroidal neovascularization by modulating AMP-activated protein kinase in macrophages and other cell types. J. Nutr. Biochem. 2014, 25, 1218-1225.
79. Richer, S.; Stiles, W.; Ulanski, L.; Carroll, D.; Podella, C. Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement. Nutrients 2013, 5, 1989-2005.
80. Maltepe, E.; Schmidt, J.; Baunoch, D.; Bradfield, C.; Simon, M. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature 1997, 386, 403-407.
81. Wen, W.; Lu, J.; Zhang, K.; Chen, S. Grape seed extract inhibits angiogenesis via suppression of the vascular endothelial growth factor receptor signaling pathway. Cancer Prev. Res. 2008, 1, 554-561.
82. Chen, Y.; Li, X.; Xing, N.; Cao, X. Quercetin inhibits choroidal and retinal angiogenesis in vitro. Graefe's Arch. Clin. Exp. Ophthalmol. 2008, 246, 373-378.
83. Zhuang, P.; Shen, Y.; Lin, B.; Zhang, W.; Chiou, G. Effect of quercetin on formation of choroidal neovascularization (CNV) in age-related macular degeneration (AMD). Eye Sci. 2011, 26, 23-29.
84. Donnini, S.; Finetti, F.; Lusini, L.; Morbidelli, L.; Cheynier, V.; Barron, D.; Williamson, G.; Waltenberger, J.; Ziche, M. Divergent effects of quercetin conjugates on angiogenesis. Br. J. Nutr. 2006, 95, 1016-1023.
85. Lavine, J.A.; Sang, Y.; Wang, S.; Ip, M.S.; Sheibani, N. Attenuation of choroidal neovascularization by β2-adrenoreceptor antagonism. JAMA Ophthalmol. 2013, 131, 376-382.
86. Wang, S.; Sorenson, C.M.; Sheibani, N. Lack of thrombospondin 1 and exacerbation of choroidal neovascularization. Arch. Ophthalmol. 2012, 130, 615-620.
87. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 1985, 260, 3440-3450.